Change the keyword or sentiment above, then click Apply.
Friday, 11 Sep 20261 update
↔ AI sentiment: Neutral
90% confidence
Emcure Allots 11,400 Shares Under ESOS, Share Capital Hits ₹189.71 Cr
Emcure Pharmaceuticals allotted 11,400 equity shares under ESOS 2013 to eligible employees.
Post allotment, issued share capital increased to 18,97,10,647 shares, aggregating Rs. 189.71 cr.
Source: BSE
Tuesday, 01 Sep 20263 updates
↔ AI sentiment: Neutral
92% confidence
Emcure Pharmaceuticals: Plans Meeting With Analysts and Investors on September 4
↔ AI sentiment: Neutral
92% confidence
Emcure to Host Investor Meet on Sep 4, 2026 in Pune
Emcure Pharmaceuticals announces analyst/investor meet on Sep 4, 2026, in Pune.
No unpublished price-sensitive info will be shared during the meeting.
Source: BSE
↗ AI sentiment: Bullish
89% confidence
CARE Reaffirms Emcure Ratings; Stable Outlook on Growth, Profit Rise
CARE reaffirmed Emcure Pharmaceuticals' ratings with a stable outlook.
Reasons include growth, diversification, profit rise, and strong capital despite increased debt.
Source: ScoutQuest
Monday, 31 Aug 20261 update
↔ AI sentiment: Neutral
91% confidence
Emcure Pharma Sets ₹3.60 Dividend, Ex-Date Sept 4
Emcure Pharmaceuticals' ex-dividend date is September 4, for a dividend of ₹3.60/share, payable on October 21.
The company has a low payout ratio (7.4% income, 14% cash flow) and 11% EPS growth over five years.
Source: Simply Wall Street
Friday, 28 Aug 20261 update
↔ AI sentiment: Neutral
84% confidence
Elara Starts 'Accumulate' on Emcure, Sets ₹2,030 Target
Elara Capital initiates Accumulate rating on Emcure Pharma with ₹2,030 target.
The rating reflects a diverse portfolio, strong global growth, and pharma partnerships.
Source: ScoutQuest